A Fever With No Clear Answer
You have a high fever, body aches, and a splitting headache. You live in rural India, Thailand, or the Philippines. Your doctor runs the standard tests — malaria, dengue, typhoid — and everything comes back negative.
What you might have is scrub typhus. And there's a good chance no one will figure that out in time.
A Disease Hidden in Plain Sight
Scrub typhus is caused by a tiny bacterium called Orientia tsutsugamushi, spread through the bite of infected chigger mites (microscopic larvae that live in vegetation). It causes an estimated one million cases per year and can be fatal if not treated promptly with the right antibiotic.
The disease is most common across a vast zone sometimes called the "tsutsugamushi triangle" — stretching from Pakistan and India through Southeast Asia, Japan, and into Australia and the Pacific islands.
Despite being both common and treatable, scrub typhus is massively underdiagnosed. Part of the problem is that it looks like so many other illnesses. Another clue — a black scab at the bite site called an "eschar" — is often absent or missed during examination.
Why Current Tests Fall Short
Most lab tests for scrub typhus target a single specific gene in the bacterium's DNA. The problem is that gene exists in just one copy per bacterial cell. When a patient has a very early or mild infection — with only a small number of bacteria in the blood — there may not be enough genetic material for the test to detect.
It's like trying to find one specific person in a massive crowd using only a single blurry photograph. If that person is far away, you'll miss them.
A Smarter Target in the Genome
Researchers from a team specializing in tropical infectious diseases developed a new genetic test called TranScrub. Instead of looking for a single-copy gene, TranScrub targets a segment of the bacterial genome that exists in many copies per cell — a repetitive genetic element called a transposase gene.
Using a target that appears hundreds of times in each cell is like handing your search team hundreds of clear photographs instead of one blurry one.
This dramatically increases the test's ability to detect the bacterium even when very few bacteria are present in a blood sample.
How the Test Was Evaluated
Researchers tested TranScrub against blood samples from 32 patients with confirmed scrub typhus and 77 patients with other diseases to check for false positives. They also applied it to 81 dried blood spot (DBS) samples — a low-cost collection method where a drop of blood is dried onto filter paper — from patients with unexplained acute fevers.
Dried blood spot testing is important because it can be done in remote areas without refrigeration, and samples can be mailed to a central lab for analysis.
TranScrub correctly identified 29 out of 32 confirmed scrub typhus cases — a sensitivity of 91 percent. It had zero false positives across 77 other-disease samples, achieving 100 percent specificity. In plain terms: when TranScrub says you have scrub typhus, you very likely do.
Among the 81 mystery fever samples, 6 (about 7.5 percent) tested positive for scrub typhus — and all 6 were confirmed by an independent sequencing method. That means scrub typhus was silently behind nearly 1 in 13 unexplained fever cases in that group.
The test's detection limit — how small an amount of bacterial DNA it can reliably find — was remarkably low, suggesting it could catch infections at the very earliest stages.
What This Means for Patients
If you live in or travel to tropical regions and develop an unexplained fever, scrub typhus should be on your doctor's radar — especially if standard tests keep coming back negative.
This test is not yet commercially available or in routine clinical use. But the dried blood spot compatibility makes it particularly promising for resource-limited settings, where most scrub typhus cases occur and where shipping blood samples to regional labs is often the only option.
Limitations Worth Noting
The study used a relatively small number of confirmed positive samples (32 cases). While the results are promising, the test will need to be validated in larger, more geographically diverse patient groups before it can be recommended for widespread clinical use.
The accuracy may also vary depending on how early in the illness the sample is collected and the local strain of the bacterium.
What Comes Next
The research team plans to pursue broader validation studies across multiple countries. If those results hold up, TranScrub could be deployed in field surveillance programs and diagnostic labs throughout South and Southeast Asia — helping to finally put a number on how many people are actually affected by this long-overlooked disease.